FeesSafety
Pluang+

Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Company Fundamentals
22 Nov 2026, 21:53 WIB
James Halley
View Source
Bullish
Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead Sciences increased its dividend by 3.8% for the 11th consecutive year, supported by strong free cash flow of $10.6 billion over nine months and a conservative payout ratio below 30%. The company maintains a dominant position in HIV therapies with blockbuster drugs like Biktarvy, which holds patent protection through 2036, and is expanding into oncology and liver disease treatments. New products such as Trodelvy and Livdelzi are driving revenue growth, while a robust pipeline of 49 clinical programs promises future innovation. This diversified portfolio and financial strength make Gilead's dividend growth sustainable.

Gilead Sciences trades at USD 166.43 on Pluang as of Nov 22, 2026 22:02 WIB, with a dividend yield of 1.97%. Despite a slight 0.06% dip in one day, the stock maintains a strong market cap of $206.43 billion. This steady trading environment complements the company's ongoing dividend growth streak highlighted in the news.

More News (GILD)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App